

Elena Campello

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2575328/publications.pdf>

Version: 2024-02-01

127
papers

3,166
citations

159585
30
h-index

189892
50
g-index

130
all docs

130
docs citations

130
times ranked

4472
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Post-Thrombotic Syndrome in Patients With a First Proximal Deep Venous Thrombosis Treated With Direct Oral Anticoagulants. <i>Angiology</i> , 2022, 73, 649-654.	1.8	6
2	Letter to the editor: Is PAI-1 a thrombotic biomarker in NASH cirrhosis?. <i>Hepatology</i> , 2022, 76, E16-E17.	7.3	1
3	Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications. <i>Liver International</i> , 2022, 42, 1229-1240.	3.9	17
4	Protein C or Protein S deficiency associates with paradoxically impaired platelet-dependent thrombus and fibrin formation under flow. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12678.	2.3	2
5	Assessing Clinically Meaningful Hypercoagulability after COVID-19 Vaccination: A Longitudinal Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1352-1360.	3.4	6
6	Risk Factors of Venous Thromboembolism in Noncritically Ill Patients Hospitalized for Acute COVID-19 Pneumonia Receiving Prophylactic-Dose Anticoagulation. <i>Viruses</i> , 2022, 14, 737.	3.3	7
7	Increased platelet aggregation in decompensated cirrhosis indicates higher risks of further decompensation and liver-related mortality. <i>Digestive and Liver Disease</i> , 2022, 54, S16-S17.	0.9	0
8	Increased platelet aggregation in patients with decompensated cirrhosis indicates higher risk of further decompensation and death. <i>Journal of Hepatology</i> , 2022, 77, 660-669.	3.7	43
9	Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey. <i>Rheumatology</i> , 2022, 61, S1136-S1142.	1.9	13
10	Global hemostatic profiling in patients with decompensated cirrhosis and bacterial infections. <i>JHEP Reports</i> , 2022, 4, 100493.	4.9	17
11	Staging the pre-procedural prophylaxis in decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2022, 54, 1130-1132.	0.9	5
12	Mechanisms of thrombosis in pancreatic ductal adenocarcinoma. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101346.	1.7	9
13	Reply to "Peripheral versus central venous blood sampling does not influence the assessment of platelet activation in cirrhosis". <i>Platelets</i> , 2022, 33, 1104-1106.	2.3	6
14	Partial F8 gene duplication (factor VIII Padua) associated with high factor VIII levels and familial thrombophilia. <i>Blood</i> , 2021, 137, 2383-2393.	1.4	20
15	Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy: Risk Factors and Prevention. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 914-919.	2.7	7
16	Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1323-1330.	2.3	40
17	The risk of arterial thrombosis in carriers of natural coagulation inhibitors: a prospective family cohort study. <i>Internal and Emergency Medicine</i> , 2021, 16, 997-1003.	2.0	6
18	Increased platelet aggregation in patients with cirrhosis and hepatocellular carcinoma: A new potential therapeutic target?. <i>Digestive and Liver Disease</i> , 2021, 53, S37-S38.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Influence of Hepatocellular Carcinoma on Platelet Aggregation in Cirrhosis. <i>Cancers</i> , 2021, 13, 1150.	3.7	21
20	Use of Glucocorticoids and Risk of Venous Thromboembolism: A Narrative Review. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 654-661.	2.7	19
21	PO-29 Plasma levels of procoagulant and anticoagulant factors in patients with acute cancer-associated thrombosis. <i>Thrombosis Research</i> , 2021, 200, S32.	1.7	0
22	Determinants of increased thrombotic tendency in NASH cirrhosis: not there yet!. <i>Transplant International</i> , 2021, 34, 1325-1327.	1.6	1
23	Coagulopathy is not predictive of bleeding in patients with acute decompensation of cirrhosis and acute-on-chronic liver failure. <i>Liver International</i> , 2021, 41, 2455-2466.	3.9	29
24	Acute kidney injury is associated with increased levels of circulating microvesicles in patients with decompensated cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 879-888.	0.9	17
25	More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC. <i>Hepatology Communications</i> , 2021, 5, 1987-2000.	4.3	16
26	Reply to "Acute kidney injury in patients with decompensated cirrhosis". <i>Digestive and Liver Disease</i> , 2021, 53, 1217-1218.	0.9	1
27	Absence of hypercoagulability after nCoV-19 vaccination: An observational pilot study. <i>Thrombosis Research</i> , 2021, 205, 24-28.	1.7	22
28	ABO blood groups and the risk of retinal vein occlusion. <i>Internal and Emergency Medicine</i> , 2021, 16, 1387-1390.	2.0	1
29	Post-operative hypercoagulable whole blood profiles in patients undergoing open thoracotomy vs video-assisted thoracoscopic surgery. <i>Blood Transfusion</i> , 2021, 19, 144-151.	0.4	4
30	Longitudinal Trend of Plasma Concentrations of Extracellular Vesicles in Patients Hospitalized for COVID-19. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 770463.	3.7	27
31	The prognostic role of ThromboDynamic Index in patients with severe sepsis. <i>Internal and Emergency Medicine</i> , 2020, 15, 163-168.	2.0	4
32	Changes in plasma circulating microvesicles in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2020, 40, 913-920.	3.9	12
33	Development and application of global assays of hyper- and hypofibrinolysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 46-53.	2.3	23
34	More Severe Hypercoagulable State in Acute COVID-19 Pneumonia as Compared With Other Pneumonia. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2020, 4, 696-702.	2.4	12
35	COVID-19 and Venous Thromboembolism in Intensive Care or Medical Ward. <i>Clinical and Translational Science</i> , 2020, 13, 1108-1114.	3.1	46
36	Endothelial Damage of the Portal Vein is Associated with Heparin-Like Effect in Advanced Stages of Cirrhosis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1173-1181.	3.4	41

#	ARTICLE	IF	CITATIONS
37	Platelet-primed interactions of coagulation and anticoagulation pathways in flow-dependent thrombus formation. <i>Scientific Reports</i> , 2020, 10, 11910.	3.3	21
38	Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study. <i>Journal of the American Heart Association</i> , 2020, 9, e018917.	3.7	31
39	How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 795-798.	2.1	5
40	Different Hypercoagulable Profiles in Patients with COVID-19 Admitted to the Internal Medicine Ward and the Intensive Care Unit. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1474-1477.	3.4	233
41	Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: a comparison between 3-factor and 4-factor prothrombin complex concentrates. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 127-131.	1.0	4
42	Platelet-Derived Microparticles Bearing PF4 and Anti-GAGS Immunoglobulins in Patients with Sepsis. <i>Diagnostics</i> , 2020, 10, 627.	2.6	12
43	Incidence of VTE in asymptomatic children with deficiencies of antithrombin, protein C, and protein S: a prospective cohort study. <i>Blood Advances</i> , 2020, 4, 5442-5448.	5.2	7
44	Viscoelastic testing in benign hematologic disorders: Clinical perspectives and future implications of point-of-care testing to assess hemostatic competence. <i>Transfusion</i> , 2020, 60, S101-S121.	1.6	2
45	Diagnosis and Treatment of Trauma-Induced Coagulopathy by Viscoelastography. <i>Seminars in Thrombosis and Hemostasis</i> , 2020, 46, 134-146.	2.7	33
46	Acute Kidney Injury in Decompensated Cirrhosis Is Associated With Both Hypocoagulable and Hypercoagulable Features. <i>Hepatology</i> , 2020, 72, 1327-1340.	7.3	60
47	Thrombotic risk following video-assisted thoracoscopic surgery versus open thoracotomy: a systematic review and meta-analysis. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2020, 30, 573-581.	1.1	3
48	Heparin challenge test in patients undergoing cardiac surgery: dealing with heparin allergy. <i>Blood Coagulation and Fibrinolysis</i> , 2020, 31, 165-169.	1.0	0
49	Increased Cardiovascular Risk Associated with Chemical Sensitivity to Perfluorooctanoic Acid: Role of Impaired Platelet Aggregation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 399.	4.1	39
50	The haemostatic system in acromegaly: a single-centre case-control study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1009-1018.	3.3	2
51	COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure. <i>Thrombosis and Haemostasis</i> , 2020, 120, 998-1000.	3.4	553
52	Whole-blood hypocoagulable profile correlates with a greater risk of death within 28 days in patients with severe sepsis. <i>Korean Journal of Anesthesiology</i> , 2020, 73, 224-231.	2.5	13
53	The relationship between pancreatic cancer and hypercoagulability: a comprehensive review on epidemiological and biological issues. <i>British Journal of Cancer</i> , 2019, 121, 359-371.	6.4	78
54	Thrombophilia, risk factors and prevention. <i>Expert Review of Hematology</i> , 2019, 12, 147-158.	2.2	54

#	ARTICLE	IF	CITATIONS
55	Thromboelastometry profiles after “in vitro” addition of a new plasma-derived factor V concentrate to whole blood from para haemophilia patients. <i>Haemophilia</i> , 2019, 25, e38-e42.	2.1	2
56	Levels of circulating microparticles in septic shock and sepsis-related complications: a case-control study. <i>Minerva Anestesiologica</i> , 2019, 85, 625-634.	1.0	26
57	“In vitro” correction of the severe factor V deficiency-related coagulopathy by a novel plasma-derived factor V concentrate. <i>Haemophilia</i> , 2018, 24, 648-656.	2.1	18
58	Contact System Activation and Cancer: New Insights in the Pathophysiology of Cancer-Associated Thrombosis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 251-265.	3.4	44
59	ABO blood group and the risk of post-thrombotic syndrome. <i>Annals of Hematology</i> , 2018, 97, 1057-1060.	1.8	7
60	Circulating microparticles in pregnant patients with primary anti-phospholipid syndrome: an exploratory study. <i>Scandinavian Journal of Rheumatology</i> , 2018, 47, 501-504.	1.1	5
61	On-treatment platelet reactivity in peripheral and coronary blood in patients undergoing primary PCI for ST-segment elevation myocardial infarction (STEMI). <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2018, 78, 281-286.	1.2	1
62	Clinical and laboratory characteristics of isolated lupus anticoagulants. <i>Thrombosis Research</i> , 2018, 165, 51-53.	1.7	9
63	Activated Platelet-Derived and Leukocyte-Derived Circulating Microparticles and the Risk of Thrombosis in Heparin-Induced Thrombocytopenia: A Role for PF4-Bearing Microparticles?. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 334-341.	1.5	34
64	Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. <i>Cancers</i> , 2018, 10, 450.	3.7	51
65	Association between ABO blood group and bleeding phenotype in patients with mild rare bleeding disorders. <i>Haemophilia</i> , 2018, 24, e428-e430.	2.1	3
66	Padua FIXa resistance to Protein S and a potential therapy for hyperactive FIXa. <i>Thrombosis Research</i> , 2018, 170, 133-141.	1.7	5
67	Peculiar laboratory phenotype/genotype relationship due to compound inherited protein C defects in a child with severe venous thromboembolism. <i>Hamostaseologie</i> , 2018, 38, 33-38.	1.9	2
68	Circulating microparticles and thrombotic risk in patients with HCV-related cirrhosis who underwent DAA treatment. <i>Journal of Hepatology</i> , 2018, 68, S538-S539.	3.7	0
69	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing’s disease. <i>Endocrine</i> , 2018, 62, 207-214.	2.3	14
70	New generation flow-cytometry to measure circulating microvesicles in cancer. <i>Thrombosis Research</i> , 2018, 164, S242-S243.	1.7	0
71	The diagnostic challenge: are we missing pulmonary embolism diagnosis in patients with syncope?. <i>Internal and Emergency Medicine</i> , 2018, 13, 965-969.	2.0	0
72	Reversal of hypercoagulability in patients with <sc>HCV</sc>-related cirrhosis after treatment with direct-acting antivirals. <i>Liver International</i> , 2018, 38, 2210-2218.	3.9	39

#	ARTICLE	IF	CITATIONS
73	Dabigatran in ibrutinib-treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases. Hematological Oncology, 2018, 36, 801-803.	1.7	4
74	Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Digestive and Liver Disease, 2017, 49, 440-445.	0.9	66
75	Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles?. Clinical Chemistry and Laboratory Medicine, 2017, 55, 934-943.	2.3	5
76	The current understanding of trauma-induced coagulopathy (TIC): a focused review on pathophysiology. Internal and Emergency Medicine, 2017, 12, 981-991.	2.0	23
77	Prothrombotic microparticles and risk of portal vein thrombosis in patients with HCV-related liver cirrhosis who underwent DAA antiviral therapy. Digestive and Liver Disease, 2017, 49, e9.	0.9	0
78	Predictors of postoperative bleeding in children undergoing cardiopulmonary bypass: A preliminary Italian study. Thrombosis Research, 2017, 153, 85-89.	1.7	8
79	Decreased hypercoagulable state in hepatitis C virus-cirrhotic patients treated with DAA: the outcome revolution. Journal of Hepatology, 2017, 66, S122.	3.7	0
80	Factor VIIa-antithrombin complex: a possible new biomarker for activated coagulation. Clinical Chemistry and Laboratory Medicine, 2017, 55, 484-488.	2.3	13
81	Circulating levels and characterization of microparticles in patients with different degrees of glucose tolerance. Cardiovascular Diabetology, 2017, 16, 118.	6.8	55
82	Factor V Leiden paradox and the occurrence of distal vein thrombosis in a large cohort of thrombotic patients. Thrombosis Research, 2017, 156, 20-22.	1.7	3
83	Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S. Thrombosis and Haemostasis, 2016, 115, 81-88.	3.4	36
84	Circulating microparticles and risk of portal vein thrombosis in patients with liver cirrhosis and hepatocellular carcinoma. Digestive and Liver Disease, 2016, 48, e37.	0.9	0
85	New Prothrombin Mutation (Arg596Trp, Prothrombin Padua 2) Associated With Venous Thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 1022-1029.	2.4	49
86	Hyperacute Valve Thrombosis After Transapical Transcatheter Aortic Valve Replacement in a Patient With Polycythemia Vera. JACC: Cardiovascular Interventions, 2016, 9, 1746-1747.	2.9	4
87	Microparticles as biomarkers of venous thromboembolic events. Biomarkers in Medicine, 2016, 10, 743-755.	1.4	46
88	Endocytosis of exogenous factor V by <i>ex vivo</i> differentiated megakaryocytes from patients with severe para haemophilia. British Journal of Haematology, 2016, 175, 517-524.	2.5	6
89	Diagnosis and management of factor V Leiden. Expert Review of Hematology, 2016, 9, 1139-1149.	2.2	39
90	Thromboelastometry profiles in patients undergoing thrombolytic therapy for acute ischaemic stroke. Thrombosis and Haemostasis, 2016, 115, 1231-1234.	3.4	12

#	ARTICLE	IF	CITATIONS
91	Perioperative coagulation assessment of patients undergoing major elective orthopedic surgery. Internal and Emergency Medicine, 2016, 11, 793-801.	2.0	18
92	Hypercoagulability detected by circulating microparticles in patients with hepatocellular carcinoma and cirrhosis. Thrombosis Research, 2016, 143, 118-121.	1.7	29
93	Short-term exposure to high levels of air pollution (nickel) and the risk of acute unprovoked proximal deep vein thrombosis in the legs. Internal and Emergency Medicine, 2016, 11, 159-162.	2.0	6
94	The Coagulative Profile of Cyanotic Children Undergoing Cardiac Surgery: The Role of Whole Blood Preoperative Thromboelastometry on Postoperative Transfusion Requirement. Artificial Organs, 2016, 40, 698-705.	1.9	18
95	Dynamics of circulating microparticles in obesity after weight loss. Internal and Emergency Medicine, 2016, 11, 695-702.	2.0	34
96	Optimal duration of anticoagulation. Thrombosis and Haemostasis, 2015, 113, 1210-1215.	3.4	21
97	Hypercoagulability in overweight and obese subjects who are asymptomatic for thrombotic events. Thrombosis and Haemostasis, 2015, 113, 85-96.	3.4	82
98	The impact of disseminated intravascular coagulation on the outcome of cancer patients with venous thromboembolism. Blood Coagulation and Fibrinolysis, 2015, 26, 709-711.	1.0	5
99	Whole blood thromboelastometry profiles in women with preeclampsia. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1793-8.	2.3	16
100	Extracellular vesicles, tissue factor, cancer and thrombosis – discussion themes of the ISEV 2014 Educational Day. Journal of Extracellular Vesicles, 2015, 4, 26901.	12.2	69
101	Circulating microparticles in umbilical cord blood in normal pregnancy and pregnancy with preeclampsia. Thrombosis Research, 2015, 136, 427-431.	1.7	32
102	Origin and levels of circulating microparticles in normal pregnancy: A longitudinal observation in healthy women. Scandinavian Journal of Clinical and Laboratory Investigation, 2015, 75, 487-495.	1.2	16
103	The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti- β_2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clinical Chemistry and Laboratory Medicine, 2015, 53, 1083-9.	2.3	32
104	Hypercoagulability detected by whole blood thromboelastometry (ROTEM®) and impedance aggregometry (MULTIPLATE®) in obese patients. Thrombosis Research, 2015, 135, 548-553.	1.7	59
105	Could Hemorrhagic and Thrombotic Risk Due to Peg-Asparaginase be Identified By Coagulative Tests Using Fibtex and Antithrombin Levels? A Single Centre Study. Blood, 2015, 126, 2305-2305.	1.4	0
106	Thromboelastometry-guided therapy of massive gastrointestinal bleeding in a 12-year old boy with severe Graft-versus-Host disease. Blood Transfusion, 2015, 13, 320-3.	0.4	1
107	Short-term exposure to high levels of air pollution as a risk factor for acute isolated pulmonary embolism. Thrombosis Research, 2014, 134, 259-263.	1.7	23
108	Circulating microparticles in carriers of prothrombin G20210A mutation. Thrombosis and Haemostasis, 2014, 112, 432-437.	3.4	14

#	ARTICLE	IF	CITATIONS
109	Evaluation of a procoagulant phospholipid functional assay as a routine test for measuring circulating microparticle activity. Blood Coagulation and Fibrinolysis, 2014, 25, 534-537.	1.0	20
110	Antithrombin Plasma Levels and Fibtet Determination in Children with Acute Lymphoblastic Leukemia Undergoing Asparaginase Treatment. Blood, 2014, 124, 5246-5246.	1.4	1
111	Thrombin Activatable Fibrinolysis inhibitor in Cancer Patients with and without Venous Thromboembolism. Thrombosis Research, 2013, 132, 484-486.	1.7	7
112	“Hypocoagulable” thromboelastography profiles in patients with cyanotic congenital heart disease: Facts or technical artifacts?. International Journal of Cardiology, 2013, 168, 2914.	1.7	8
113	Treatment of venous thromboembolism: the single-drug approach. Clinical Practice (London, England), 2013, 13, 107-114.	0.1	1
114	Thromboelastographic evaluation of coagulative profiles in pig-to-monkey kidney xenotransplantation. Xenotransplantation, 2013, 20, 89-99.	2.8	9
115	Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thrombosis and Haemostasis, 2013, 110, 378-385.	3.4	55
116	Factor IX activity/antigen ratio and the risk of first unprovoked venous thromboembolism. Thrombosis and Haemostasis, 2013, 109, 755-756.	3.4	2
117	Hemostatic changes in pregnancy. Reviews in Health Care, 2013, 4, 31-39.	0.1	6
118	ABO blood groups and the risk of venous thrombosis in patients with inherited thrombophilia. Blood Transfusion, 2013, 11, 250-3.	0.4	32
119	Prothrombin Mutation Conveying Antithrombin Resistance. New England Journal of Medicine, 2012, 367, 1069-1070.	27.0	6
120	Aspirin and recurrent venous thromboembolism in patients with symptomatic atherosclerosis: retrospective cohort study. Journal of Thrombosis and Haemostasis, 2012, 10, 2205-2206.	3.8	8
121	Factor VIIa-antithrombin complexes plasma levels in cancer patients with and without thrombosis. Thrombosis Research, 2012, 129, 818-819.	1.7	3
122	Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis. Thrombosis and Haemostasis, 2012, 108, 633-639.	3.4	27
123	Whole blood rotation thromboelastometry (ROTEM [®]) in nine severe factor V deficient patients and evaluation of the role of intraplatelets factor V. Haemophilia, 2012, 18, 463-468.	2.1	24
124	Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thrombosis Research, 2011, 127, 473-477.	1.7	122
125	Factor VIIa-antithrombin complexes in children with ischemic stroke. Thrombosis Research, 2011, 128, 303-304.	1.7	10
126	Thrombophilia and the risk of post-thrombotic syndrome: retrospective cohort observation. Journal of Thrombosis and Haemostasis, 2010, 8, 211-213.	3.8	18

#	ARTICLE	IF	CITATIONS
127	Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis. Thrombosis and Haemostasis, 2010, 103, 1188-1192.	3.4	32